Aurobindo Pharma is set to increase its stake in its China joint venture. The company will acquire an additional 20 percent for USD 5.12 million. This move is part of a larger plan to eventually own 70 percent of Luoxin Aurovitas Pharma. The deal is expected to be completed within three months.